NCT07185945View on ClinicalTrials.gov

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

March 31, 2029

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG

Zanzalintinib

60 mg orally once daily

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

collaborator

Advent Health

UNKNOWN

lead

Guru Sonpavde

OTHER